The Time Is Right: Proteome Biology of Stem Cells

Stem Cell and Leukemia Proteomics Laboratory, Faculty of Medical and Human Sciences, University of Manchester, Christie Hospital, Manchester M20 9BX, UK.
Cell stem cell (Impact Factor: 22.27). 04/2008; 2(3):215-7. DOI: 10.1016/j.stem.2008.02.003
Source: PubMed


In stem cell biology, there is a growing need for advanced technologies that may help to unravel the molecular mechanisms of self-renewal and differentiation. Proteomics, the comprehensive analysis of proteins, is such an emerging technique. To facilitate interactions between specialists in proteomics and stem cell biology,a new initiative has been undertaken, supported by the Human Proteome Organization (HUPO) and the International Society for Stem Cell Research (ISSCR). Here we present the Proteome Biology of Stem Cells Initiative (PBSCI) and report on its goals and future activities.

Download full-text


Available from: Andrew J K Williamson,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Over 1000 patients have participated worldwide in clinical trials exploring the therapeutic value of bone marrow-derived cells in ischemic heart disease. Meta-analysis evaluation of this global effort indicates that adult stem cell therapy is in general safe, but yields a rather modest level of improvement in cardiac function and structural remodeling in the setting of acute myocardial infarction or chronic heart failure. Although promising, the potential of translating adult stem cell-based therapy from bench to bedside has yet to be fully realized. Inter-trial and inter-patient variability contribute to disparity in the regenerative potential of transplanted stem cells with unpredictable efficacy on follow-up. Strategies that mimic the natural embryonic program for uniform recruitment of cardiogenic progenitors from adult sources are currently tested to secure consistent outcome. Guided cardiopoiesis has been implemented with mesenchymal stem cells obtained from bone marrow of healthy volunteers, using a cocktail of secreted proteins that recapitulate components of the endodermal secretome critical for cardiogenic induction of embryonic mesoderm. With appropriate validation of this newly derived cardiopoietic phenotype, the next generation of trials should achieve demonstrable benefit across patient populations.
    Journal of Molecular and Cellular Cardiology 10/2008; 45(4-45):523-529. DOI:10.1016/j.yjmcc.2008.09.122 · 4.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cells (SCs) are defined by their combined abilities to both self-renew indefinitely in vitro and differentiate into adult cell types. One of the major driving forces of SC research is that SCs may provide a potentially unlimited source for cell-replacement therapies in regenerative medicine. However, the identification of SCs and their progenies at different stages, and the success of cell-replacement therapies, which form the basis of SC engineering, will depend on the ability to characterize and ultimately isolate homogeneous primary stem or progenitor cell populations to a large degree. Furthermore, the recent identification of cancer stem cells (CSCs) opens a new avenue for developing novel therapeutic strategies by targeting a specific subset of cancer cells with self-renewal and proliferation capacity. Crucial to these tasks will be the discovery of novel plasma membrane-associated SC markers. In this review, we focus on the seminal contribution that membrane proteomics could make to further clinical applications of SCs by providing tools for purification and identification of SCs and their progenies at each stage of differentiation, as well as, to understand the underlying mechanisms of SC differentiation. The need to standardize biological SC models before embarking on international SC proteomics efforts is discussed.
    Proteomics 12/2008; 8(23-24):4946-57. DOI:10.1002/pmic.200800312 · 3.81 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The focus of regenerative medicine is rebuilding damaged tissues by cell transplantation or implantation of bioartificial tissues. In either case, therapies focus on adult stem cells (ASCs) and embryonic stem cells (ESCs) as cell sources. Here we review four topics based on these two cell sources. The first compares the current performance of ASCs and ESCs as cell transplant therapies and the drawbacks of each. The second explores somatic cell nuclear transfer (SCNT) as a method to derive ESCs that will not be immunorejected. The third topic explores how SCNT and ESC research has led to the ability to derive pluripotent ESCs by the dedifferentiation of adult somatic cells. Lastly, we discuss how research on activation of intrinsic adult stem cells and on somatic cell dedifferentiation can evolve regenerative medicine from a platform consisting of cell transplantation to one that includes the chemical induction of regeneration from the body's own cells at the site of injury. Developmental Dynamics 237:3648–3671, 2008. © 2008 Wiley-Liss, Inc.
    Developmental Dynamics 12/2008; 237(12):3648 - 3671. DOI:10.1002/dvdy.21774 · 2.38 Impact Factor
Show more